Zydus Lifesciences Limited has informed the Exchange regarding a press release dated Jun 14, 2024, titled "Zydus receives tentative approval from USFDA for Azilsartan Medoxomil and Chlorthalidone Tablets".
Press Release Jun 14 2024
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release announcing that it received tentative approval from the USFDA for Azilsartan Medoxomil and Chlorthalidone Tablets. The tablets are indicated for the treatment of high blood pressure and will be manufactured in Ahmedabad. The press release also notes that the drug had significant annual sales in the United States.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release May 24 2024
- Press Release May 22 2024
- Press Release May 17 2024
- Press Release May 11 2024
- Press Release May 09 2024
Later from Zydus Lifesciences
- Press Release Jun 28 2024
- Press Release Jul 04 2024
- Press Release Jul 10 2024
- Press Release (Revised) Jul 10 2024
- Press Release Jul 17 2024
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences